MUMBAI, India -
Oct. 11, 2025 -
PRLog -- In the aftermath of the devastating loss of at least 21 children due to contaminated cough syrup containing toxic diethylene glycol (DEG), healthcare safety advocates are urgently calling for comprehensive reforms in drug safety monitoring systems across India's pharmaceutical sector. The tragic deaths, primarily occurring in Madhya Pradesh after children consumed Coldrif syrup manufactured by Sresan Pharmaceuticals, have exposed critical vulnerabilities in the nation's drug safety infrastructure that demand immediate attention.
Cliorbit, a Mumbai-based pharmacovigilance services (https://cliorbit.in/
pharmacovigilance/)
provider, represents this emerging approach to accessible drug safety. The company's platform integrates artificial intelligence and real-world data analytics to provide comprehensive safety monitoring at a fraction of traditional costs, specifically designed for the Indian pharmaceutical ecosystem.
"Our mission is simple – make life-saving safety technology accessible to every pharmaceutical company, regardss
Account Phone Number